Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial [0.03%]
生物标志物的鉴定可预测前列腺特异性膜抗原正电子发射断层扫描阳性低复发前列腺癌补救手术的成功：BioPoP试验的结果
Sabine Riethdorf,Sophie Knipper,Fabian Falkenbach et al.
Sabine Riethdorf et al.
Background and objective: Prostate-specific membrane antigen (PSMA) radioligand imaging allows early detection of recurrence of prostate cancer (PC). While circulating tumor cells (CTCs) have proven prognostic value in me...
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy [0.03%]
机器人辅助与传统开放部分肾切除术的随机对照ROBOCOP II试验的2年随访：肿瘤学、功能和生活质量结果
Caelán Max Haney-Aubert,Luise Gottstein,Marie Angela Sidoti Abate et al.
Caelán Max Haney-Aubert et al.
Background and objective: Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) ...
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy [0.03%]
达鲁莫单抗治疗前列腺切除术后或初始放疗后的生化复发或低转移性雄激素敏感型前列腺癌的II期开放标签研究（ARAMON）
Andrew L Laccetti,Matthew R Smith,Howard I Scher et al.
Andrew L Laccetti et al.
Background and objective: Darolutamide is an androgen receptor inhibitor (ARI) with low blood-brain barrier penetration, potentially resulting in low reactive testosterone increases and less feminizing adverse events (AEs...
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy [0.03%]
自体脂肪源性再生细胞治疗根治性前列腺切除术后阴茎勃起功能障碍的随机、双盲、安慰剂对照研究
Sabrina Toft Hansen,Ditte Caroline Andersen,Charlotte Harken Jensen et al.
Sabrina Toft Hansen et al.
Background and objective: Erectile dysfunction (ED) following radical prostatectomy (RP) has a negative impact on quality of life. Herein, the aim was to assess the effectiveness of autologous adipose-derived regenerative...
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration) [0.03%]
预测新型前列腺癌患者总生存期的模型：在多西他赛临床试验中对男性转移性初始雄激素敏感前列腺癌患者的分层及其治疗效果（STOPCAP协作项目）
Susan Halabi,Bin Luo,Chenxi Yu et al.
Susan Halabi et al.
Background and objective: This study aimed to develop and validate a prognostic model for overall survival (OS) in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), using clinical factors from phase 3...
Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials [0.03%]
伴有心血管合并症的过动膀胱患者使用米拉贝隆的有效性和安全性：随机试验的事后分析
Amy Lockefeer,Arianne Schild,Swapneel Anaokar et al.
Amy Lockefeer et al.
Background and objective: We conducted a post hoc analysis to evaluate the efficacy and safety of mirabegron in patients with overactive bladder (OAB) and cardiovascular risk comorbidity (CRC) using data from an integrate...
Gut Microbiome as a Lifestyle Risk Factor Associated with Prostate Cancer [0.03%]
肠道微生物组与前列腺癌相关的新型生活方式风险因素
Michael A Liss,James R White,Molly Doris et al.
Michael A Liss et al.
Background and objective: Most prostate cancer prevention strategies suggest lifestyle modifications, which lack personalization. Gut microbiome is increasingly recognized as an influencing factor in nongastrointestinal c...
Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014 [0.03%]
约书亚·J·米克斯。尿路上皮癌：表达谱亚型在肌层浸润性膀胱癌新辅助治疗中的作用是什么？Eur Urol Focus. 在线发表 ahead of print. https://doi.org/10.1016/j.euf.2025.11.014
Gottfrid Sjödahl,Pontus Eriksson,Mattias Höglund
Gottfrid Sjödahl
WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms [0.03%]
WATER III：一项关于水解术与经尿道激光前列腺剜除术治疗下尿路症状的前瞻性部分随机试验
Manuel Ritter,Johannes Stein,Neil Barber et al.
Manuel Ritter et al.
Background and objective: Aquablation and laser enucleation of the prostate (LEP) are treatments for alleviation of lower urinary tract symptoms (LUTS) that have not yet been directly compared in a prospective randomized ...
Reply to Ingmar Wolff, Maximilian Burger, Sabine Brookman-May, and Matthias May's Letter to the Editor re: Re: Mattia Longoni, Leonardo Quarta, Donato Cannoletta, et al. Long-term Functional Outcomes and Decision Regret after Robot-assisted Radical Prostatectomy: An Experienced Surgeon Series. Eur Urol Focus. In press. https://doi.org/10.1016/j [0.03%]
针对Ingmar Wolff，Maximilian Burger，Sabine Brookman-May和Matthias May来信的回信关于：Mattia Longoni，Leonardo Quarta，Donato Cannoletta等机器人辅助根治性前列腺切除术后的长期功能预后及决策遗憾：一位经验丰富外科医生系列研究回信
Mattia Longoni,Giorgio Gandaglia,Alberto Briganti et al.
Mattia Longoni et al.